BPMC / Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion more_horizontal

Blueprint Medicines delivered an exceptional quarter with a positive reception for Ayvakit in its first full-quarter post-launch. More than 800 patien more_horizontal

Blueprint Medicines (BPMC) came out with a quarterly loss of $2.20 per share versus the Zacks Consensus Estimate of a loss of $2.39. This compares to more_horizontal

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indicati more_horizontal

Blueprint Medicines announced increased revenue and decreased losses. The company's lead therapy, Ayvakit, is now approved for three indications. more_horizontal

Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advan more_horizontal

Blueprint Medicines just got a critical green light from regulators for Ayvakit. This treats a rare and often debilitating blood disorder affecting 1 more_horizontal

Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multipl more_horizontal